Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × Tamoxifen × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 245 Carcinoma, Intraductal, Noninfiltrating 21 Breast Carcinoma In Situ 17 Breast Neoplasms, Male 11 Neoplasm Metastasis 10 Neoplasms 6 Inflammatory Breast Neoplasms 6 Breast Cancer Female 4 Obesity 3 Carcinoma, Ductal, Breast 3 Sleep Wake Disorders 2 Hot Flashes 2 Endometrial Neoplasms 2 ER+ Breast Cancer 2 Carcinoma, Lobular 2 Vitamin D Deficiency 1 Triple Negative Breast Neoplasms 1 Sarcoma 1 Risk Reduction Behavior 1 Recurrence 1 Pulmonary Fibrosis 1 Primary Breast Cancer 1 Premenopausal Breast Cancer 1 Precancerous Conditions 1 Patient Acceptance of Health Care 1 Paget's Disease, Mammary 1 Nutrition Disorders 1 Non Metastatic Breast Cancer 1 Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer 1 Neoplasm Recurrence, Local 1

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Capecitabine 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Trastuzumab 2 Gemcitabine 2 Docetaxel 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡